Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
121
resultados
Última actualización
29/05/2025 [07:41:00]
Resumen de: WO2025102119A1
The present disclosure relates generally to the use of agents, such as oligonucleotides, to improve, increase, restore or retain the integrity of the blood brain barrier; and/or to reduce the deposition or accumulation of and/or promote the clearance of, amyloid-β. The disclosure also related to agents, such as oligonucleotides, that increase, promote or restore the level or amount of VE-cadherin in a cell, and are thus useful in the methods of the present disclosure. The present disclosure also relates to the use of such agents to treat diseases and conditions associated with damage to the blood brain barrier, including diseases and conditions associated with neuroinflammation and neurodegeneration, as well as diseases and conditions associated with amyloid-β deposition, including Alzheimer's disease (AD), Cerebral amyloid angiopathy (CAA), Lewy body dementia (LBD) and traumatic brain injury (TBI).
Resumen de: AU2023371945A1
4-Aminopyrrolo2,I-f1,2,4triazine compounds of formula I for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of 4- aminopyrrolo2,1-fl,2,4triazine compounds or analogs thereof, in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer's disease, diabetes, and osteoarthritis).
Resumen de: US2025163114A1
Nonsense-mediated mRNA decay (NMD) polypeptides, nucleic acids encoding NMD polypeptides, and methods of using such polypeptides and nucleic acids in the treatment of ALS and in screening for agents for the treatment of ALS are described.
Resumen de: WO2025106603A1
The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient, such as Alzheimer's Disease. Such methods entail administering a pharmaceutical composition comprising an immunogenic fragment of Aβ capable of inducing a beneficial immune response in the form of antibodies to Aβ. The immunogenic fragments comprise linear or multivalent peptides of Aβ. Pharmaceutical compositions comprise the immunogenic fragment chemically linked to a carrier molecule which may be administered with an adjuvant.
Resumen de: WO2025103475A1
The present invention relates to a heterocyclic carbonyl derivative modulator, a preparation method therefor, and the use thereof. Specifically, the present invention relates to a compound represented by general formula (II-B), a preparation method therefor, a pharmaceutical composition containing said compound, and a use thereof as a modulator in the treatment of Alzheimer's disease, schizophrenia, pain, addiction, and sleep disorders, wherein each substituent in general formula (II-B) is as defined in the description.
Resumen de: US2025161286A1
The disclosure relates to compositions and methods of using a pomalidomide derivative that exhibits improved pharmacological effects as compared to pomalidomide for treating brain diseases. The pomalidomide derivative exhibits excellent binding to cereblon, has almost no cytotoxicity, is unlikely to cause teratogenic adverse effects, can control TNF-α expression, exhibits excellent in vivo pharmacokinetic stability while suppressing oxidative stress, ameliorates a decrease in motor function which is a symptom of Parkinson's disease, and increases tyrosine hydroxylase expression which is reduced by Parkinson's disease, and thus can be used for preventing or treating brain diseases such as Parkinson's disease.
Resumen de: US2025161408A1
The present invention relates to a peptide, and to a pharmaceutical composition and a heterocomplex comprising the peptide. Furthermore, the present invention relates to the peptide, the pharmaceutical composition, or the heterocomplex for use in a method of preventing or treating Alzheimer's disease and/or for use in a method of preventing or treating type 2 diabetes. The present invention further relates to the peptide, the pharmaceutical composition, or the heterocomplex for use in a method of diagnosing Alzheimer's disease and/or for use in a method of diagnosing type 2 diabetes. The present invention also relates to a kit for the in vitro or in vivo detection of amyloid fibrils or aggregates, or for the diagnosis of Alzheimer's disease and/or type 2 diabetes in a patient. Moreover, the present invention relates to the use of the peptide or of the heterocomplex in an in vitro assay for the detection of monomeric islet amyloid polypeptide (LAPP), monomeric Aβ40 (42), amyloid fibrils, or amyloid aggregates.
Resumen de: US2025161387A1
Provided is a method for preventing, improving or treating Alzheimer's disease, dementia or brain function degeneration in a subject in need, including administering to the subject a composition comprising purified mushroom β-glucan, wherein the purified β-glucan is derived from mushroom mycelium or its fermentation product, wherein the purity of the purified mushroom β-glucan is 60% or above.
Resumen de: US2025161420A1
The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient, such as Alzheimer's Disease. Such methods entail administering a pharmaceutical composition comprising an immunogenic fragment of Aβ capable of inducing a beneficial immune response in the form of antibodies to Aβ. The immunogenic fragments comprise linear or multivalent peptides of Aβ. Pharmaceutical compositions comprise the immunogenic fragment chemically linked to a carrier molecule which may be administered with an adjuvant.
Resumen de: WO2025103285A1
Use of an innate phagocytosis-promoting polypeptide in preparing a drug for treating Alzheimer's disease.
Resumen de: EP4556554A1
Provided are a Bifidobacterium longum subsp. infantis for alleviating Parkinson's disease and a use thereof, and the Bifidobacterium longum subsp. infantis for alleviating Parkinson's disease is named as Bifidobacterium longum subsp. infantis BI03 strain, with a deposit number of CGMCC No.24473 and deposit date of Mar. 7, 2022. The strain can significantly alleviate the symptoms of Parkinson's disease, specifically manifested in: alleviating Parkinson's disease-related dyskinesia and corticosterone elevation; weakening the neuroinflammation associated with Parkinson's disease; promoting glutathione and weakening brain oxidative stress damage.
Resumen de: EP4556014A1
Provided is a method for preventing, improving or treating Alzheimer's disease, dementia or brain function degeneration in a subject in need, including administering to the subject a composition comprising purified mushroom β-glucan, wherein the purified β-glucan is derived from mushroom mycelium or its fermentation product, wherein the purity of the purified mushroom β-glucan is 60% or above.
Resumen de: WO2025101004A1
The present invention relates to a 6-aryl imidazo(2,1-b)thi/oxazole-2-carboxilic acid derivative. The compound according to the present invention acts as a JNK3 inhibitor capable of acting specifically on JNK3. The compound according to the present invention has a relatively high inhibitory activity against JNK3 compared to inhibitory activities against JNK1 and JNK2, and thus can be used as a therapeutic agent for Alzheimer's disease with low risk of side effects.
Resumen de: KR20250067698A
본 발명은 6-Aryl imidazo2,1-bthi/oxazole-2-carboxilic acid 유도체에 관한 것으로, 본 발명에 따른 화합물은 JNK3에 대해 특이적으로 작용할 수 있는, JNK3 억제제로 작용한다. 본 발명에 따른 화합물은 JNK1 및 JNK2에 대한 억제 활성에 비하여 JNK3에 대한 억제 활성이 상대적으로 높기 때문에 부작용의 위험성이 낮은 알츠하이머병 치료제로서 활용할 수 있다.
Resumen de: WO2025100469A1
According to the present invention, it is found that a snake venom metaloproteinase SVMP (snake venom metalloproteinase) from a snake belonging to the family Viperidae, the family Elapidae or the like decomposes Aβ and cuts the Aβ at an α-position to suppress the formation of Aβ fibrils. When a protein containing a metaloproteinase domain of SVMP is administered or a gene for the protein is introduced and is expressed in the brain, the formation of Aβ fibrils can be suppressed and consequently Alzheimer's disease can be treated.
Resumen de: US2025152539A1
The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.
Resumen de: US2025152543A1
The invention is a method for treating levodopa naïve patients with Parkinson's disease by orally administering a controlled release levodopa formulation twice a day to the levodopa naïve patient and the method provides an improvement of a patient's motor state as determined by patient's Parkinson's disease diary, provides a reduction of from about 10%-40% in the patient's tremor, dyskinesia, and/or mobility and/or provides a reduction in the patient's Movement Disorders Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores by at least 3 points.
Resumen de: US2025152542A1
The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.
Resumen de: US2025152590A1
The invention provides a series of substituted aryl pyrimidine compounds and the use of these compounds as therapeuties to treat or prevent neurodegenerative disorders, including Parkinson's disease. Compounds of the invention are also able to treat the symptoms of such diseases and therefore represent a new treatment modality for ameliorating chronic and acute conditions. The compounds of the invention are capable of selectively potentiating the activity of the Nurr1:RXRα heterodimer, and are able to treat diseases or conditions associated with aberrant Nurr1:RXRα function. The invention further provides methods for treating neurodegenerative disorders by administration of Nurr1:RXRα activating agents.
Resumen de: US2025152659A1
A method for preventing or treating Parkinson's disease including administering a patient in need thereof a pharmaceutical composition including a polypeptide, the peptide having an amino acid sequence I or II: I: FPGSDRF (SEQ ID NO: 1)-Z; II: X-FPGSDRF (SEQ ID NO: 1)-Z; S represents phosphorylated serine; X and Z independently represents an amino acid or an amino acid sequence; X is selected from F, (R)9 (SEQ ID NO: 2), (R)9-F (SEQ ID NO: 3), 6-aminohexanoic acid, 6-aminohexanoic acid-F, 6-aminohexanoic acid-(R)9 (SEQ ID NO: 2), 6-aminohexanoic acid-(R)9-F (SEQ ID NO: 3); and Z is selected from (G)n-RGD or A-(G)n-RGD (SEQ ID NO: 4), where n is an integer greater than or equal to 0, in the range of 0-10.
Resumen de: WO2025098365A1
Disclosed are a levodopa nasal spray, a preparation method therefor, and use thereof. The levodopa nasal spray comprises levodopa or a pharmaceutically acceptable salt thereof, an absorption enhancer, a suspending agent, an antioxidant, a wetting agent, and an antimicrobial agent. The levodopa nasal spray enhances the stability of levodopa, increases olfactory region deposition of the drug, improves nasal-to-brain delivery efficiency, can effectively treat Parkinson's disease while reducing the occurrence of symptom fluctuations, and has suitable viscosity.
Resumen de: US2025152540A1
The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.
Resumen de: US2025152541A1
The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.
Resumen de: US2025152747A1
Provided herein are expression cassettes for expressing a transgene in a cell, wherein the transgene encodes a GCase polypeptide. Also provided are methods to treat Gaucher Disease or GBA-PD. Further provided herein are vectors (e.g., rAAV vectors), viral particles, pharmaceutical compositions, and kits for expressing an GCase polypeptide in an individual in need thereof.
Nº publicación: EP4551228A1 14/05/2025
Solicitante:
WOOLSEY PHARMACEUTICALS INC [US]
Woolsey Pharmaceuticals, Inc
Resumen de: WO2024011094A1
The present invention relates to the treatment of an ALS patient having disease onset of at least 24 months prior to initiation of treatment with fausdil. Fasudil is administered at a dose of 60-240 mg/day according to specific treatment regimens. This results in an anticipated 25-50% reduction in the average decline over at least three months as measured using the revised ALS Functional Rating Scale.
BOPI
Sede Electrónica
